"I'd expect much if not all of the EUA Drug Substance/Drug Product supply at launch to come from Catalent."
It appears that you are correct. “Catalent has partnered closely with Humanigen to develop and supply lenzilumab for clinical trials,” commented Karen Flynn, President of Catalent Biologics and Chief Commercial Officer."
Also of note in that announcement is the following. "Humanigen’s investigational monoclonal antibody, lenzilumab, was developed using Catalent’s proprietary GPEx® cell line development technology." That's the platform capable of yielding 7 grams of product per liter.